SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Singleton who wrote (4763)7/6/1998 4:36:00 PM
From: Vector1  Read Replies (1) of 6136
 
Peter,
I bought more shares today. Averaging down. The problem is I can't keep doing this indefinitely. I think my problem is that I don't look at it like a trader. I have been sucessful across industry as a long term investor but generally lousy as a trader.
AGPH has a successful drug which is clearly the best in its class. The Geneva conference raises issues about Viracept growth rate, but sales are not likely to go down for the next few years at least. Indeed they are likely to increase. The three deals announced will cut into short term earnings but make great sense long term. They have already built a sales force and an infrastructure and are leveraging off of it. We are at the point where positive news has been greatly discounted . At this point the chances of a positive surprise is much greater than a negative one.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News